Like everything else within this world, medical products which can adapt themselves to their environment have the highest chance of success. We believe that value comes not only from the product itself but from the product in combination with the context in which it is placed. This context is not static, it evolves constantly, integrating new research, technologies, and practices.
Dynamic health economic software allows for real-time adjustments and more accurate predictions of the value of innovations for every context, allowing innovators to adapt to new evidence, policy changes, and specific settings. This empowers health tech companies to keep pace with the ever-evolving needs of the healthcare industry.
We recognize that the clinical value of new innovations in biotech, pharma, and medtech is not fixed. Instead, it depends on the specific settings in which they are used. Traditional evaluations of these innovations often provide a limited view, focusing on cost-effectiveness and health outcomes in a single setting. These evaluations yield conclusions that, while useful, do not capture the full potential of the innovations.
From our experience in academia, we observed that this limited approach often overlooks significant potential and fails to fully exploit the clinical value of new products. Companies miss opportunities to demonstrate the broader benefits of their innovations, which can lead to underutilization and undervaluation in the market.
We believe in shifting from static evaluations to dynamic assessments of value. By evaluating cost-effectiveness, cost-utility, and cost-benefit across various settings, we can unlock more value from these technologies. Our software enables comprehensive evaluations, showing variations in value across different contexts. This dynamic approach empowers stakeholders—doctors, hospitals, and others—to see the added value of innovations in their specific settings, rather than relying on generic evaluations.
We call this 'Health Economic Software’. Health Economic Software helps companies maximize the clinical value of their innovations, ensuring they reach their full potential and improve healthcare outcomes.
CEO | HTA expert | Business developer
Tim Govers has a PhD in the use of decision models to make health care decisions for both the population and individual patients. After obtaining his PhD, he analyzed the added value of medical products for a great number of medical companies from his role at the Radboudumc and MedValue. In this role, he performed and supervised many model-based analyses of the value of diagnostic and prognostic tests.
CTO | Modeling expert | Software developer
Stan Wijn completed his PhD research on the analysis of the added value of medical interventions in subgroups of the population using a wide variety of statistical approaches. He has developed various applications that are used to demonstrate the value of medical interventions to healthcare professionals, such as physicians. He has also developed predictive algorithms to make predictions about treatment outcomes for patients.
All the right tools for the dynamic assessment of the value of a technology
Medip Analytics has a wide experience over technologies and disease areas.
Technologies
Disease areas
Schedule a demo to see how Health Economic Software can improve the market uptake of your products.